SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet's Disease
On August 14, 2025, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2025 and provided a business update. Following...
140 Views
SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet's Disease
On July 31, 2025, Soligenix, Inc. (SNGX) announced encouraging results from the Phase 2a clinical trial of SGX-945 (dusquetide) for the treatment...
174 Views
SNGX: Multiple Catalysts Upcoming in 2H25
Soligenix, Inc. (SNGX) has a number of important catalysts ahead in the second half of 2025. The company is currently conducting the Phase 3...
163 Views
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL
On May 9, 2025, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2025 and provided a business update. Enrollment...
149 Views
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses
On April 14, 2025, Soligenix, Inc. (SNGX) announced interim results from the ongoing, open label, investigator initiated study (IIS) evaluating...
199 Views